In human cell tests, the most accurate editor reduced bystander edits by more than 80% while maintaining high activity at the target site, addressing a major safety concern.

The work is preclinical, but shows substantial reductions in unintended edits at CF-related sites, indicating potential for long-lasting therapies pending further development.

A joint team from the University of Pennsylvania and Rice University has refined base-pair editing technology to swap single DNA letters with much higher precision, reducing unintended edits and improving safety for potential genetic therapies, including cystic fibrosis.

Funding for the study came from the NIH, NSF, and the Cystic Fibrosis Foundation, with authors noting the data reflect their findings and do not necessarily represent funders’ views.

The work was conducted at Penn Engineering and Rice University, supported by NIH and NSF grants, and the paper detailing the findings was published in Molecular Therapy in mid-January 2026.

Authors highlight that the technology enables accurate modeling of disease mutations in lab cells, informing drug testing and patient-specific treatment strategies.

In cystic fibrosis models, the team introduced and corrected CF-related mutations in human epithelial cells, demonstrating both editing and reversal of these mutations with improved cellular function.

CF research suggests potential for long-lasting or permanent treatments, offering benefits over some current therapies by enabling precise single-letter edits.

Beyond CF, the refined editor provides a broader toolkit for precisely modeling and correcting single-letter mutations, supporting more personalized medicine approaches.

Researchers emphasize a precision akin to editing a single document letter, aiming to limit edits to the targeted letter without affecting neighboring letters, marking a conceptual safety and specificity advance in gene editing.

While therapies like Trikafta help CF patients, precise base editing could offer durable solutions if off-target risks are minimized and long-term benefits are realized.

Technical advance comes from shortening and stiffening the DNA-targeting linker and adjusting the editor’s interaction with DNA, tightening the leash to prevent off-target edits.